Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.

[1]  N. Urgancı,et al.  Effect of Interferon-α and Combined Interferon-α with Lamivudine Treatment on Anthropometric Measurements in Children with Chronic Hepatitis B , 2017, Annals of Nutrition and Metabolism.

[2]  A. Bertoletti,et al.  Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks , 2017, Viruses.

[3]  K. Chayama,et al.  Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses , 2017, Journal of medical virology.

[4]  Shuqin Zhang,et al.  Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.

[5]  P. Vajro,et al.  An update on the strategies used for the treatment of chronic hepatitis B in children , 2016, Expert review of gastroenterology & hepatology.

[6]  B. McMahon,et al.  Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta‐analysis , 2016, Hepatology.

[7]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[8]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[9]  K. Kowdley,et al.  Management of chronic hepatitis B infection , 2015, BMJ : British Medical Journal.

[10]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[11]  C. Thio,et al.  Global elimination of mother-to-child transmission of hepatitis B: revisiting the current strategy. , 2015, The Lancet. Infectious diseases.

[12]  Zong-tang Sun,et al.  Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial , 2014, PLoS medicine.

[13]  E. Gane,et al.  Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study , 2014, Gut.

[14]  D. Corley,et al.  Prevention of vertical transmission of hepatitis B: an observational study. , 2014, Annals of internal medicine.

[15]  V. Nobili,et al.  Management of chronic hepatitis B in children: An unresolved issue , 2014, Journal of gastroenterology and hepatology.

[16]  Xueping Yu,et al.  Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment , 2013, Hepatitis monthly.

[17]  G. Mieli-Vergani,et al.  Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. , 2013, Journal of hepatology.

[18]  N. Krishnani,et al.  Cure for immune‐tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? , 2013, Journal of viral hepatitis.

[19]  Tanshi Li,et al.  Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. , 2012, Antiviral research.

[20]  I. Ushiro-Lumb,et al.  Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. , 2012, Gastroenterology.

[21]  P. Rosenthal,et al.  Pegylated interferon for chronic hepatitis C in children affects growth and body composition: Results from the pediatric study of hepatitis C (PEDS‐C) trial , 2012, Hepatology.

[22]  Mei‐Hwei Chang.  Natural history and clinical management of chronic hepatitis B virus infection in children , 2008, Hepatology international.

[23]  B. Choe,et al.  Long-term Therapeutic Efficacy of Lamivudine Compared With Interferon-α in Children with Chronic Hepatitis B: The Younger the Better , 2007, Journal of pediatric gastroenterology and nutrition.

[24]  D. Vergani,et al.  Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. , 2006, The Journal of pediatrics.

[25]  M. Korzon,et al.  Tolerance of interferon‐alpha therapy in children with chronic hepatitis B , 2004, Journal of paediatrics and child health.

[26]  K. Kang,et al.  [Pretreatment ALT level and histologic activity as predictors of HBeAg loss in lamivudine treatment for chronic hepatitis B]. , 2004, The Korean journal of hepatology.

[27]  M. Jonas,et al.  Clinical trial of lamivudine in children with chronic hepatitis B. , 2002, The New England journal of medicine.

[28]  J. Sarles,et al.  Impact of chronic hepatitis B and interferon‐α therapy on growth of children , 2001 .

[29]  P. Rosenthal,et al.  American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.

[30]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.